189 related articles for article (PubMed ID: 23038213)
21. Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line.
Legrand-Poels S; Schoonbroodt S; Piette J
Biochem J; 2000 Aug; 349 Pt 3(Pt 3):765-73. PubMed ID: 10903137
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-6: a potential biomarker of resistance to multitargeted receptor tyrosine kinase inhibitors in castration-resistant prostate cancer.
Kutikov A; Makhov P; Golovine K; Canter DJ; Sirohi M; Street R; Simhan J; Uzzo RG; Kolenko VM
Urology; 2011 Oct; 78(4):968.e7-11. PubMed ID: 21982018
[TBL] [Abstract][Full Text] [Related]
23. Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner.
Wu F; Lin Y; Cui P; Li H; Zhang L; Sun Z; Huang S; Li S; Huang S; Zhao Q; Liu Q
Cancer Chemother Pharmacol; 2018 Jun; 81(6):999-1006. PubMed ID: 29605876
[TBL] [Abstract][Full Text] [Related]
24. Intraperitoneal administration of a small interfering RNA targeting nuclear factor-kappa B with paclitaxel successfully prolongs the survival of xenograft model mice with peritoneal metastasis of gastric cancer.
Inoue M; Matsumoto S; Saito H; Tsujitani S; Ikeguchi M
Int J Cancer; 2008 Dec; 123(11):2696-701. PubMed ID: 18798274
[TBL] [Abstract][Full Text] [Related]
25. Diverse effects of zinc on NF-kappaB and AP-1 transcription factors: implications for prostate cancer progression.
Uzzo RG; Crispen PL; Golovine K; Makhov P; Horwitz EM; Kolenko VM
Carcinogenesis; 2006 Oct; 27(10):1980-90. PubMed ID: 16606632
[TBL] [Abstract][Full Text] [Related]
26. Identification of lipidomic profiles associated with drug-resistant prostate cancer cells.
Ingram LM; Finnerty MC; Mansoura M; Chou CW; Cummings BS
Lipids Health Dis; 2021 Feb; 20(1):15. PubMed ID: 33596934
[TBL] [Abstract][Full Text] [Related]
27. Dexamethasone potentiates the antiangiogenic activity of docetaxel in castration-resistant prostate cancer.
Wilson C; Scullin P; Worthington J; Seaton A; Maxwell P; O'Rourke D; Johnston PG; McKeown SR; Wilson RH; O'Sullivan JM; Waugh DJ
Br J Cancer; 2008 Dec; 99(12):2054-64. PubMed ID: 19050703
[TBL] [Abstract][Full Text] [Related]
28. Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.
Kim SM; Lee SY; Cho JS; Son SM; Choi SS; Yun YP; Yoo HS; Yoon DY; Oh KW; Han SB; Hong JT
Eur J Pharmacol; 2010 Apr; 631(1-3):1-9. PubMed ID: 20056115
[TBL] [Abstract][Full Text] [Related]
29. Crosstalk between epithelial-mesenchymal transition and castration resistance mediated by Twist1/AR signaling in prostate cancer.
Shiota M; Itsumi M; Takeuchi A; Imada K; Yokomizo A; Kuruma H; Inokuchi J; Tatsugami K; Uchiumi T; Oda Y; Naito S
Endocr Relat Cancer; 2015 Dec; 22(6):889-900. PubMed ID: 26311513
[TBL] [Abstract][Full Text] [Related]
30. Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer.
Ito Y; Kikuchi E; Tanaka N; Kosaka T; Suzuki E; Mizuno R; Shinojima T; Miyajima A; Umezawa K; Oya M
BMC Cancer; 2015 Apr; 15():324. PubMed ID: 25926105
[TBL] [Abstract][Full Text] [Related]
31. Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer.
Gong Y; Chippada-Venkata UD; Galsky MD; Huang J; Oh WK
Prostate; 2015 May; 75(6):616-27. PubMed ID: 25560638
[TBL] [Abstract][Full Text] [Related]
32. Current second-line treatment options for patients with castration resistant prostate cancer (CRPC) resistant to docetaxel.
Arsov C; Winter C; Rabenalt R; Albers P
Urol Oncol; 2012; 30(6):762-71. PubMed ID: 20884252
[TBL] [Abstract][Full Text] [Related]
33. Combined prognostic value of both RelA and IkappaB-alpha expression in human non-small cell lung cancer.
Zhang D; Jin X; Wang F; Wang S; Deng C; Gao Z; Guo C
Ann Surg Oncol; 2007 Dec; 14(12):3581-92. PubMed ID: 17899287
[TBL] [Abstract][Full Text] [Related]
34. Estrogen receptor α and aromatase polymorphisms affect risk, prognosis, and therapeutic outcome in men with castration-resistant prostate cancer treated with docetaxel-based therapy.
Sissung TM; Danesi R; Kirkland CT; Baum CE; Ockers SB; Stein EV; Venzon D; Price DK; Figg WD
J Clin Endocrinol Metab; 2011 Feb; 96(2):E368-72. PubMed ID: 21106711
[TBL] [Abstract][Full Text] [Related]
35. NF-kappaB activation enhances cell death by antimitotic drugs in human prostate cancer cells.
Parrondo R; de las Pozas A; Reiner T; Rai P; Perez-Stable C
Mol Cancer; 2010 Jul; 9():182. PubMed ID: 20618955
[TBL] [Abstract][Full Text] [Related]
36. Emerging targets to monitor and overcome docetaxel resistance in castration resistant prostate cancer (review).
Magadoux L; Isambert N; Plenchette S; Jeannin JF; Laurens V
Int J Oncol; 2014 Sep; 45(3):919-28. PubMed ID: 24969394
[TBL] [Abstract][Full Text] [Related]
37. Suppression of NF-kappaB activity by parthenolide induces X-ray sensitivity through inhibition of split-dose repair in TP53 null prostate cancer cells.
Watson C; Miller DA; Chin-Sinex H; Losch A; Hughes W; Sweeney C; Mendonca MS
Radiat Res; 2009 Apr; 171(4):389-96. PubMed ID: 19397439
[TBL] [Abstract][Full Text] [Related]
38. Dual PI3K/mTOR inhibitor NVP-BEZ235 sensitizes docetaxel in castration resistant prostate cancer.
Yasumizu Y; Miyajima A; Kosaka T; Miyazaki Y; Kikuchi E; Oya M
J Urol; 2014 Jan; 191(1):227-34. PubMed ID: 23954373
[TBL] [Abstract][Full Text] [Related]
39. Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer.
Mahon KL; Lin HM; Castillo L; Lee BY; Lee-Ng M; Chatfield MD; Chiam K; Breit SN; Brown DA; Molloy MP; Marx GM; Pavlakis N; Boyer MJ; Stockler MR; Daly RJ; Henshall SM; Horvath LG
Br J Cancer; 2015 Apr; 112(8):1340-8. PubMed ID: 25867259
[TBL] [Abstract][Full Text] [Related]
40. Phase II study of cytarabine in men with docetaxel-refractory, castration-resistant prostate cancer with evaluation of TMPRSS2-ERG and SPINK1 as serum biomarkers.
Dhani NC; Emmenegger U; Adams L; Jongstra J; Tannock IF; Sridhar SS; Knox JJ; Day JR; Groskopf J; Joshua AM
BJU Int; 2012 Sep; 110(6):840-5. PubMed ID: 22313860
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
